<DOC>
	<DOCNO>NCT02939989</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety co-administration ABT-493/ABT-530 plus sofosbuvir ( SOF ) plus ribavirin ( RBV ) hepatitis C virus ( HCV ) genotype ( GT ) 1 - 6-infected participant ( include non-cirrhotic , cirrhotic participant ) experience virologic failure AbbVie parent clinical study .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ABT-493/ABT-530 Combination With Sofosbuvir Ribavirin Participants With Hepatitis C Virus Who Did Not Respond Treatment Previous AbbVie Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Participants experience virologic failure treatment ABT 493/ABT530 AbbVie hepatitis C virus ( HCV ) parent study . Participants experience virologic failure receive ombitasvir/paritaprevir/r + dasabuvir ( 3D ) , ombitasvir/paritaprevir/r ( 2D ) AbbVie HCV parent study may enrol AbbVie 's discretion . Cirrhotic participant must compensate cirrhosis , ( ChildPugh score less equal 6 ) screen current past evidence ChildPugh B C Classification clinical history liver decompensation , include ascites note physical exam , hepatic encephalopathy esophageal variceal bleeding . Cirrhotic participant must absence hepatocellular carcinoma ( HCC ) indicate negative ultrasound ( US ) , compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) within 3 month prior Screening negative US Screening . History severe , lifethreatening significant sensitivity study drug drug component . Female participant pregnant , breastfeed consider become pregnant study 4 month last dose study drug , direct per local ribavirin label . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator , failure AbbVie HCV parent study due nonvirologic reason . Positive test result screen hepatitis B surface antigen ( HBsAg ) . Screening laboratory analysis show creatinine clearance le 30 mg/dL . Discontinuation previous AbbVie HCV clinical study reason virologic failure ( e.g. , nonadherence , lose followup , and/or occurrence adverse event ) . Receipt HCV treatment fail treatment regimen AbbVie HCV parent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Virologic failure</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>HCV Genotype 3 ( HCV GT3 )</keyword>
	<keyword>HCV Genotype 5 ( HCV GT5 )</keyword>
	<keyword>Chronic Hepatitis C ( HCV )</keyword>
	<keyword>HCV Genotype 4 ( HCV GT4 )</keyword>
	<keyword>HCV Genotype 2 ( HCV GT2 )</keyword>
	<keyword>HCV Genotype 1 ( HCV GT1 )</keyword>
	<keyword>HCV Genotype 6 ( HCV GT6 )</keyword>
	<keyword>Non-cirrhotics</keyword>
</DOC>